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EDITORIAL
Editorial comment on: Measurement of serum isoform [–2]proPSA derivatives
shows superior accuracy to magnetic resonance imaging in the diagnosis of
prostate cancer in patients with a total prostate-specific antigen level of
2–10 ng/ml
Early detection of prostate cancer (PCa), and especially the
detection of clinically significant disease, remains one of the
most important issues in the urology field. The objective is to
reduce the overdiagnosis and overtreatment of those
patients who are at low risk of progression and eventually
death from PCa.
Since its introduction, prostate-specific antigen (PSA) has
shown low accuracy in predicting PCa, not discriminating it
from other, benign conditions. In recent years, new iso-
forms of PSA have been introduced in clinical practice,
with promising results. Notably, [–2]proPSA (p2PSA) was
shown to be more accurate than PSA and percentage free
PSA in predicting PCa and to correlate more closely with
high-grade diseases [1]. However, a great deal of interest
was generated in the urological community by the intro-
duction of the Prostate Health Index (PHI), a mathematical
algorithm that combines p2PSA, free PSA and total PSA. Of
the PSA derivatives, the PHI was shown to be the best
predictor of PCa, in particular in those patients with a total
PSA value of 2–10 ng/ml (the so-called grey zone) [2,3],
but also in many other subgroups (e.g. patients with previ-
ous negative biopsies, men with positive family history,
young patients and obese men).
Beside serum markers, magnetic resonance imaging
(MRI), with its ability to display and differentiate minor soft
tissue details, has been proposed as an effective tool to
investigate the presence of PCa. T2-weighted imaging
(T2WI) provides excellent differentiation of anatomical
zones of the prostate, and may correlate with PCa Gleason
scores [4], but it has low accuracy for the detection and
localization of PCa when considered alone. In particular,
the diagnosis of PCa has benefited from the development
of multiparametric MRI (mpMRI), which combines T2WI, dif-
fusion-weighted imaging and dynamic contrast-enhanced
imaging. Indeed mpMRI was shown to be an accurate
technique to localize PCa and to improve risk stratification
[5]. However, a prostate biopsy is still required to confirm
the presence of PCa, and MRI-targeted biopsy showed a
better cancer detection rate than traditional systematic
biopsy in naïve patients and particularly in those with pre-
viously negative biopsies [6].
For the first time, Furuya et al. [7] compared the accuracy
of the p2PSA derivatives and MRI in discriminating between
patients with and without PCa, and most importantly high-
grade PCa. Although retrospective and limited in numbers,
this study suggests some new perspective for the clinical
management of suspected PCa. According to previous
literature, PHI was the most accurate method for suggesting
a diagnosis of PCa at biopsy, while MRI was shown to have
the best specificity for high-grade PCa. Thus, the authors sug-
gest that PHI could be more useful than MRI in predicting
the presence of PCa at biopsy (even in a screening setting),
and MRI may be more useful than the PHI in predicting the
presence of significant diseases (in patients who are sus-
pected of having PCa from screening tests, avoiding
unnecessary biopsies).
It is important to emphasize that nowadays PCa diagnosis
is still based on biopsy, and that PSA and digital rectal exam-
ination remain the primary tools for the decision to perform
a biopsy. In uncertain cases such as asymptomatic men with
a normal digital rectal examination and a PSA between 2 and
10 ng/ml, the guidelines of the European Association of
Urology suggest offering further diagnostic options such as
serum markers (e.g. PHI) and performing mpMRI, especially
when a clinical suspicion of PCa persists after negative
biopsies [8].
Further research is clearly necessary. First of all, a greater
number of patients and the evaluation of the mpMRI are
needed to draw definitive conclusions.
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